<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357888</url>
  </required_header>
  <id_info>
    <org_study_id>V00018 PC 2 06</org_study_id>
    <secondary_id>2014-004387-38</secondary_id>
    <nct_id>NCT02357888</nct_id>
  </id_info>
  <brief_title>Assessment of V0018 2.5 mg Effect on Craving</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled, Cross-over Study of the Effect of a 2.5 mg Nicotine Lozenge on Smoking Craving</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the reduction of craving and its time course after
      administration of V0018 2.5 mg compared to placebo in healthy highly dependant smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Questionnaire for Smoking Urges Brief (QSU-Brief) (10 items)</measure>
    <time_frame>15 minutes</time_frame>
    <description>Change from study baseline to 15 minutes after treatment intake for the QSU-brief total score and demonstrate any earlier effect.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy Highly Dependant Smokers</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group sequence: Test Product on Day 1 and Placebo on Day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group sequence: Placebo on Day 1 and Test Product on Day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0018</intervention_name>
    <description>Oromucosal - Single dose</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oromucosal - Single dose</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged 18 to 64 years

          -  Smoking ≥ 20 cigarettes/day continuously for the last two years

          -  With a first cigarette smoked within 30 min after waking

          -  Not currently in the process of quitting smoking

        Exclusion Criteria:

        Related to pathologies

          -  Current or recurrent buccal lesions which, in the opinion of the investigator, would
             interfere with the assessment of the different parameters

          -  Hyposalivation or asialia

          -  Intolerance to lactose, or any pathology that could cause endogenous production of
             carbon monoxide (CO)

        Related to treatments

          -  Use of antidepressants within the last three months

          -  Use of sedatives, hypnotics, tranquilizers or any other addictive agents within the
             last 3 months

          -  Routine use of tobacco other than cigarettes

          -  Regular use for more than one week of any treatment for smoking cessation (gum, patch,
             inhaler, lozenge, tablet, bupropion, varenicline) and other smokeless tobacco products
             (including e-cigarettes) within three months

          -  History of hypersensitivity to nicotine, peanut, soya or to any of the excipients of
             study treatment

          -  Intolerance to fructose

          -  History of phenylketonuria (aspartame)

        For women of childbearing potential:

          -  Is pregnant or in post-partum period or a nursing mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Françoise MD TONNER</last_name>
    <role>Study Director</role>
    <affiliation>Pierre Fabre Medicament</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gieres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine replacement therapy</keyword>
  <keyword>craving</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

